StockNews.com assumed coverage on shares of Bio-Path (NASDAQ:BPTH – Free Report) in a report published on Sunday morning. The firm issued a sell rating on the stock.
Bio-Path Trading Up 2.6 %
BPTH opened at $0.82 on Friday. The business’s 50-day moving average is $0.97 and its two-hundred day moving average is $1.50. Bio-Path has a 1 year low of $0.61 and a 1 year high of $12.37.
Hedge Funds Weigh In On Bio-Path
An institutional investor recently bought a new position in Bio-Path stock. Armistice Capital LLC bought a new stake in Bio-Path Holdings, Inc. (NASDAQ:BPTH – Free Report) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 97,000 shares of the company’s stock, valued at approximately $194,000. Armistice Capital LLC owned about 4.66% of Bio-Path at the end of the most recent reporting period. Institutional investors own 5.74% of the company’s stock.
Bio-Path Company Profile
Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.
Featured Stories
- Five stocks we like better than Bio-Path
- Manufacturing Stocks Investing
- Disney’s Magic Strategy: Reinventing the House of Mouse
- What Makes a Stock a Good Dividend Stock?
- Volatility in Semis? 3 Stable Alternatives to NVIDIA and SMCI
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- Vertiv’s Cool Tech Makes Its Stock Red-Hot
Receive News & Ratings for Bio-Path Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path and related companies with MarketBeat.com's FREE daily email newsletter.
